Literature DB >> 24554612

Secondary tumors of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a 10-year experience.

Lindsay Waters1, Quisheng Si, Nancy Caraway, Dina Mody, Gregg Staerkel, Nour Sneige.   

Abstract

Determining whether a pancreatic mass is a primary or secondary neoplasm is necessary for appropriate treatment. We reviewed our experience using endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of pancreatic tumors to identify clinical and cytopathologic characteristics of metastatic disease. We reviewed all cases of tumors metastatic to the pancreas evaluated at The University of Texas MD Anderson Cancer Center and The Methodist Hospital in Houston, Texas during the period from 2002 to 2012. The review included cytologic specimens, clinical history, radiologic findings, primary tumor type, and clinical follow-up. We identified 66 patients with disease metastatic to the pancreas for which cytologic material was available: 38 (58%) men and 28 (42%) women, with an average age of 63 years (range, 40-89 years). Most metastases (98%) were single lesions, and nearly half were located in the head of the pancreas (30/66). The most common site of origin for these metastases was kidney (27 [41%] cases). Follow-up information was available for 65 (98%) patients, and duration of follow-up ranged from <1 to 10 years (mean, 2.3 years). Thirty-three patients (50%) were alive at the time of the most recent follow-up contact. Of the 25 patients with metastatic renal cell carcinoma, clear cell type, 19 (76%) were alive at the time of the most recent follow-up. It was concluded that metastases may mimic primary pancreatic carcinomas both clinically and cytologically. Ancillary studies in conjunction with clinical history are necessary for the accurate diagnosis of FNAs of secondary pancreatic tumors.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  EUS-FNA; metastatic tumors; pancreas; pancreatic neoplasms; secondary tumors of pancreas

Mesh:

Year:  2014        PMID: 24554612     DOI: 10.1002/dc.23114

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

1.  Integrin-linked kinase overexpression promotes epithelial-mesenchymal transition via nuclear factor-κB signaling in colorectal cancer cells.

Authors:  Hong Shen; Jun-Li Ma; Yan Zhang; Gan-Lu Deng; Yan-Ling Qu; Xiao-Ling Wu; Jing-Xuan He; Sai Zhang; Shan Zeng
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

2.  Pancreatic metastases from ocular malignant melanoma: the use of endoscopic ultrasound-guided fine-needle aspiration to establish a definitive cytologic diagnosis: a case report.

Authors:  Diogo Turiani Hourneaux De Moura; Danielle Azevedo Chacon; Ryan Tanigawa; Martin Coronel; Spencer Cheng; Éverson L A Artifon; José Jukemura; Eduardo Guimarães Hourneaux De Moura
Journal:  J Med Case Rep       Date:  2016-12-01

3.  Metastatic renal cell carcinoma from a native kidney of a renal transplant patient diagnosed by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) biopsy.

Authors:  Yaseen Alastal; Tariq A Hammad; Ehsan Rafiq; Mohamad Nawras; Osama Alaradi; Ali Nawras
Journal:  J Kidney Cancer VHL       Date:  2015-04-20

4.  Asymptomatic Pancreatic Metastasis from Renal Cell Carcinoma Diagnosed 21 Years after Nephrectomy.

Authors:  Megumi Zianne; Naoki Takahashi; Akihiko Tsujibata; Kazuhiro Miwa; Yoshinori Goto; Yutaka Matano
Journal:  Case Rep Gastrointest Med       Date:  2017-08-30

5.  Metastatic tumors to the pancreas: Balancing clinical impression with cytology findings.

Authors:  Mohamed A Abdallah; Kimberlee Bohy; Ashwani Singal; Chencheng Xie; Bhaveshkumar Patel; Morgan E Nelson; Jonathan Bleeker; Ryan Askeland; Ammar Abdullah; Khalil Aloreidi; Muslim Atiq
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

Review 6.  Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer.

Authors:  Takeshi Okamoto
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.